American Association for Cancer Research’s Virtual Annual Meeting – April 27-28, 2020

Company Product Description Indication Status
Alligator Bioscience AB, of Lund, Sweden ATOR-1015 Bispecific antibody targeting CTLA4 and OX40 Metastatic cancer Data from ongoing phase I trial showed doses have so far been well-tolerated; to date 18 patients with varying cancers (colon, eye melanoma, pancreatic, ovarian, gallbladder, gastric and skin) have been treated 
Alpine Immune Sciences Inc., of Seattle ALPN-202 Conditional CD28 co-stimulator and dual checkpoint inhibitor Advanced solid tumors or lymphoma refractory or resistant to standard therapy Presented design for phase I Neon-1 study; 2-part study will include dose-escalation and expansion cohorts; objective responses will be assessed by RECIST v1.1 for solid tumors and Lugano criteria for lymphoma; pharmacokinetics and pharmacodynamics will also be evaluated
Aptose Biosciences Inc., of San Diego CG-806 FLT3/BTK kinase inhibitor Chronic lymphocytic leukemia; small lymphocytic leukemia; non-Hodgkin lymphoma Stable trough plasma concentrations reached by day 8 in first 2 participants treated at dose levels 1 and 2 in phase I trial; on-target pharmacologic activity shown by plasma inhibitory assays, with reporter cells exposed to patient plasma for 6 hours; phospho-BTK was reduced after exposure to plasma from patient treated at dose level 1 and abrogated with plasma from patient treated at dose level 2; results were similar for phosphorylation of PDGFR-alpha for SYK, which lies in same signaling pathway as BTK, and for ERK
Astrazeneca plc, of Cambridge, U.K. Durvalumab Anti-PD-L1 antibody Breast cancer Data from I-Spy 2 trial showed adding durvalumab to PARP inhibitor olaparib and standard-of-care preoperative chemotherapy improved outcomes for women with stage II/III, high-risk, HER2-negative disease; patients who received the combination achieved complete eradication of their cancer from breast and axillary lymph nodes at the time of surgery at a greater rate than patients treated with chemotherapy alone (37% vs. 20%); that degree of response met the threshold for graduation, meaning there is greater than 85% predicted probability of success if that combination was tested against standard chemotherapy in phase III trial of 300 neoadjuvant patients
Compugen Ltd., of Holon, Israel COM-701 Anti-PVRIG antibody Advanced solid tumors Results from ongoing phase I trial in patients who have exhausted all available standard therapies showed signals of antitumor activity with high disease control rate in both monotherapy and combination arms (69% and 75%, respectively), including 2 confirmed partial responses and durable responses of more than 6 months across cohorts, in heavily pretreated patients
Epsilogen Ltd., of London Mov-18 IgE IgE antibody, specific for anti-folate receptor alpha Advanced cancer Interim phase I data from first 24 patients, most of whom had ovarian cancer, showed drug was well-tolerated; investigators believe there was transient signal of antitumor activity in CT scans and in a temporary CA125 biomarker decrease for 1 patient with ovarian cancer
Iteos Therapeutics SA, of Gosselies, Belgium EOS-850 A2A receptor antagonist Advanced solid tumors Data from phase I portion in 21 patients showed drug was well-tolerated, two 2 partial responses in heavily pretreated patients; pharmacokinetic analysis demonstrated good dose-proportionality through 80 mg BID, the recommended phase II dose
Macrogenics Inc., of Rockville, Md. Flotetuzumab Bispecific CD123 x CD3 DART molecule Refractory acute myeloid leukemia Data from ongoing phase I/II trial suggested TP53 mutational status correlated with an immune-infiltrated tumor microenvironment that was associated with response to flotetuzumab; among patients with TP53 mutated AML treated with flotetuzumab, 45.5% (5/11) showed evidence of anti-leukemic activity, including 2 with complete remission (CR), 1 with a CR with partial hematologic recovery, and 1 with morphologic leukemia-free state per International Working Group criteria; median overall survival (OS) of flotetuzumab-treated patients with TP53 abnormalities was 4 months (range 1.25-21.25), compared to an estimated median OS of 1 month 
Merck & Co. Inc., of Kenilworth, N.J. Keytruda (pembrolizumab) Anti-PD-1 antibody Metastatic melanoma Interim data from cohort B of phase I Keynote-555 trial testing 400-mg every six-week (Q6W) dosing regimen showed an overall response rate of 38.6% (n=17/44) in patients who received Q6W, the primary endpoint
Rgenix Inc., of New York RGX-104 Immunotherapy targeting LXR Refractory or relapsed solid tumors Initial results from phase Ib trial in combination with docetaxel in heavily pretreated patients showed overall response rate (ORR) in all evaluable patients was 22%, with a disease control rate (DCR) of 56%; across cohorts 2 and 3, where target RGX-104 pharmacodynamic effects were achieved, the ORR was 33% with a 67% DCR; clinical activity was associated with increases in T-cell activation markers exceeding that generally observed with RGX-104 alone
Ribon Therapeutics Inc., of Cambridge, Mass. RBN-2397 PARP7 inhibitor Cancer Preclinical data showed oral dosing resulted in complete tumor regression in a NCI-H1373 lung cancer xenograft model and induced complete tumor regressions with tumor-specific adaptive immune memory in an immunocompetent cancer model; the therapeutic effect of RBN-2397 was shown to be dependent on tumor-derived type I IFN signaling
Ribon Therapeutics Inc., of Cambridge, Mass. RBN012759 PARP14 inhibitor Cancer Preclinical data showed RBN012759 effectively binds to and inhibits PARP14, and PARP14 inhibition with RBN012759 reversed IL-4-driven gene expression in macrophages; treatment of primary tumor cultures induced an inflammatory response similar to that seen using an anti-PD1/anti-CTLA4 checkpoint inhibitor combination
Sutro Biopharma Inc., of South San Francisco STRO-002 Antibody-drug conjugate Ovarian cancer Interim phase I data in heavily pretreated patients showed in 75% (15/20), dose levels of 2.9 mg/kg or higher resulted in 1 partial response and 14 stable disease; 13 patients had a ≥50% reduction or normalization of CA-125, including 6 confirmed responses, 6 unconfirmed responses and 1 prolonged CA-125 normalization; of those 13 patients, 1 is not yet evaluable under RECIST criteria
Theratechnologies Inc., of Montreal TH-1902 and TH-1904 Peptide-drug conjugates Cancer Preclinical in vivo data showed both drugs demonstrated high accumulation of the conjugates in ovarian tumors with low accumulation in healthy ovary tissue.; compared to treatments using doxorubicin or docetaxel, TH-1902 and TH-1904 were both found to have better efficacy, at equivalent dose, while not inducing weight loss nor decreasing lymphocytes
Vaccinex Inc., of Rochester, N.Y. Pepinemab Monoclonal antibody targeting semaphorin 4D Non-small-cell lung cancer Updated interim results from phase Ib/II Classical-Lung study in combination with anti-PD-L1 checkpoint inhibitor Bavencio (avelumab, EMD Serono) showed 81% of immunotherapy-naïve patients (17/21) have experienced disease control, either a partial response (5/21 patients) or stable disease (12/21 patients); of those, 4 have achieved durable clinical benefit of greater than 1 year, and 6 have achieved durable clinical benefit of greater than 6 months
Verastem Inc., of Boston VS-6766 plus defactinib RAF/MEK inhibitor plus FAK inhibitor KRAS-mutant advanced solid tumors Phase I data showed in patients in low-grade serous ovarian cancer cohort, 4 patients responded, for overall response rate of 67%; median time on treatment was 20.5 months; in non-small-cell lung cancer cohort, 1 achieved partial response and 8 achieved disease control

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments